- 专利标题: PTEFb inhibiting macrocyclic compounds
-
申请号: US16497578申请日: 2018-03-22
-
公开(公告)号: US11242356B2公开(公告)日: 2022-02-08
- 发明人: Ulrich Lücking , Daniel Hog , Clara Christ , Ulrike Sack , Franziska Siegel , Philip Lienau , Nicolas Werbeck
- 申请人: Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft
- 申请人地址: DE Leverkusen; DE Berlin
- 专利权人: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- 当前专利权人: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- 当前专利权人地址: DE Leverkusen; DE Berlin
- 代理机构: Wilson Sonsini Goodrich & Rosati
- 优先权: EP17163419 20170328
- 国际申请: PCT/EP2018/057326 WO 20180322
- 国际公布: WO2018/177889 WO 20181004
- 主分类号: C07D498/18
- IPC分类号: C07D498/18 ; C07D213/61 ; C07D239/30 ; C07D498/08
摘要:
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
公开/授权文献
- US20200347079A1 NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS 公开/授权日:2020-11-05
信息查询